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ABSTRACT
Background: Congenital rubella syndrome (CRS) 
caused by rubella infection in uterine, is a major public 
health problem among women of child bearing age as it 
causes serious complications including foetal death or 
abnormalities including cardiovascular, ophthalmologic, 
respiratory and hearing impairment.  Though there is 
evidence of rubella infection amongst the population 
under the expanded programme on immunization (epi) 
surveillance programme, there is no documented 
evidence of laboratory confirmed congenital rubella 
syndrome cases in Zambia. A report is given on four cases 
of CRS that were identified and confirmed during routine 
activities of the national measles surveillance program in 
Zambia. Clinical data on the symptomatic cases were 
collected and serum samples tested for rubella IgM to 
confirm the cases.
Case presentation: The first confirmed case was a baby 
girl presented to the Neonatal Intensive Care unit of the 
University Teaching Hospital for low birth weight and 
hypothermia. At seven weeks, the girl was found to have 
cataracts, spleno-hepatomegaly, microcephaly, and 
patent ductus arteriosus (PDA). The baby tested positive 
to rubella IgM antibodies. The second case was a baby 
boy who was first seen at the University Teaching 
Hospital at three weeks and on examination was found to 
have bilateral cataracts, congenital heart disease and 
microcephaly. Rubella Immunoglobulin M (IgM) results 
were positive. The third case, a girl, was seen at twelve 
weeks and brought in for slow growth rate. On 
examination, the girl was found to have bilateral 
cataracts, microcephaly and developmental delay. The 
fourth case is a girl who was brought to the hospital for 
failure to thrive, tachypnea and fever. On further 
investigations there was evidence of cataracts, patent 
ductus arteriosus. At eight weeks, she tested positive for 
rubella IgM antibodies.
Conclusion: The clinical symptoms and laboratory 
evidence of rubella infection confirmed congenital 
rubella syndrome in the four patients. There is an urgent 
need for surveillance of congenital rubella syndrome and 
a baseline rubella sero-prevalence survey in Zambia in 
order to determine the burden of the disease and use this 
data to direct policy in terms of interventions for 
supportive treatment, control and possible elimination of 
rubella infection through immunization with measles-
rubella vaccine. 
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childbearing age causing serious consequences 
including miscarriage, foetal death or an infant 
born with defects [1].  Although an effective 
vaccine against rubella is available, CRS 
remains a major public health problem with a 
total of 121,344 cases reported from 167 
countries to World Health Organisation (WHO) 
in 2009, showing a significant decrease from 
67,894 during 2000 in 102 WHO member 
states.  The greatest part of the decrease was in 
the United States of America and Europe of 
nearly 100%, followed by the East 
Mediterranean Region (EMRO) at 35%.  All 
these regions had set elimination goals and 
introduced a rubella containing vaccine (RCV) 
routine.  In contrast, 20, 14 and 12 fold 
increases were reported in the African region 
(AFRO), as well as the South East Asia and 
Wes te rn  Pac i f i c  reg ions  (SEARO) ,  
respectively.  In 2009,165 CRS cases were 
reported from 75 WHO member states globally. 
 [2,3] Studies by Cutts et al. [3] indicating 
proportions of women susceptible to rubella 
(sero-negative) in the Africa region report less 
than 10% in 13, 10-25% in 20 and more than 
25% in 12 countries.  Zambia is estimated to be 
in the 10-25%group.  Cutts et al. [4] also 
document that 10% of 20 patients with 
congenital cataracts and 12% of 34 with 
congenital heart disease in Tanzania in 1980/81 
and 1985/86 had other symptoms compatible 
with CRS.  Zimbabwe recorded 18 cases of 
CRS in 1978, and 10% of first legal abortions 
related to rubella infection were reported from 
South Africa. Tanzania, Senegal and Uganda 
have also reported occasional cases of CRS [4]. 
In Zambia, there are no specific programmatic 
goals relating to the elimination or control of 
rubella disease and its consequences.  The 
measles surveillance programme, a national 
case-based surveillance programme running 
since 2003 and supported by the WHO, has an 
overall goal to investigate and document the 
number of children suspected of measles 
infection under the age of 15 years presenting 
with fever and rash for measles primarily then 
rubella.  Though there is evidence of rubella 
infection amongst this population under 
surveillance, there is no documented evidence 
of laboratory-confirmed CRS cases in Zambia.  
Using a model by Miller et al. [5] and data 
stemming from a study by Watts [6] on rubella 
antibodies in a sample of Lusaka mothers, Cutts 
et al. [3] estimated the incidence of CRS to be at  
123/100 000 live births in Zambia [5-7]. 
Early diagnosis of infant rubella infection in 
CRS cases may allow for the reversal of certain 
disabilities as well as the disruption of 
continued virus spreading as it has been 
documented that children born with rubella 
infection may continue to shed the virus for 
even up to one year and hence should be 
considered infectious.  In order to monitor the 
presence of CRS and control the continued 
spread of rubella infection, laboratory-backed 
routine surveillance is a necessity.
This article describes four case reports of CRS 
that were identified and confirmed during 
routine activities of the national measles 
surveillance programme in Zambia.  Clinical 
data on the symptomatic cases were collected 
and serum samples tested for rubella IgM to 
confirm the cases. 
Documenting the existence of CRS cases is 
important and emphasizes the need to establish 
the burden of disease in order to direct policy on 
control and possible elimination of this 
devastating condition.
CASE  PRESENTATION
We present four confirmed cases of CRS seen at 
the Teaching Hospital (UTH), Lusaka, Zambia 
between April 2012 and   January 2013. 
Serological confirmation was performed using 
rubella–specific IgM (Immunoglobulin M) 
using ELISA. This was performed using the 
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Siemens Enzygnost® Anti-Rubella Virus/IgM 
assay, which is a qualitative and quantitative 
based immune assay for the determination of 
specific IgM antibodies to rubella virus in 
human serum or plasma.  To prevent false 
positives due to rheumatoid factor (RF), pre-
treatment with RF absorbent was implemented.  
The RF also binds specific IgG, thus increasing 
sensitivity for detection of IgM. The difference 
in colour intensity/optical density between the 
antigen well and the control antigen well (? OD) 
gives the measure of the immunochemical 
reactivity of the rubella virus specific IgM 
antibodies in the sample.  Any ? OD > 0.2 
implies positive acute rubella infection, <0.1 is 
negative and otherwise is indeterminate. [8]
Case 1
A term low birth weight baby girl was seen and 
treated in the first week of life for hypothermia 
and neonatal sepsis. Her birth weight was 1.7 kg 
and head circumference was 33cm. On physical 
examination, she was noted to be in mild 
respiratory distress with a hyperactive 
precordium, marked tachycardia and a mild 
systolic murmur in the left sternal border with 
no hepatomegaly. Initial echocardiographic 
(ECHO) exam showed; patent ductus arteriosus 
and peripheral pulmonary stenosis. The mother 
was a 28 year old, para 2 with unremarkable 
antenatal history.  At seven week, the baby 
presented with generalised lymphadenopathy, 
bilateral cataracts, conjunctivitis, tachycardia, 
hepatomegaly, splenomegaly and head 
circumference of 34cm.  She had gained weight 
to 2.4 kg.  A clinical diagnosis of congenital 
TORCH infection possibly congenital rubella 
syndrome was entertained. The diagnosis was 
confirmed with positive rubella IgM. Rapid 
Plasma Reagin (RPR) was negative. The child 
was jointly followed-up by the paediatrics, 
cardiology and ophthalmology teams. 
Further detailed inquiry of the mother antenatal 
history reviewed that she had a minor rash at six 
weeks of pregnancy which she 'contracted' from 
a neighbour's child.
During follow-up, she was treated and 
discharged for pneumonia and poor growth at 12 
weeks. She was notably microcephalic with 
t h
head circumference 34.5cm(below 5  
percentile), weighed 2.34 kg and height 49cm 
(WHO weight-for-height z score <-2 standard 
deviation. At 12 weeks clinic review she had a 
cough, and tachypnoic (respiration rate at 
o
84/minute) and fever (38.6 C) of 3 days 
duration.  Weight at this point was 2.43kg.  She 
had course crepitations bilaterally.  On the 
cardiovascular system, S1 and S2 were heard 
and noted to be tachycardic but there were no 
added sounds.  Liver and spleen were both still 
palpable.  Bilateral cataracts were also noted.  
She was readmitted with a diagnosis of 
Pneumonia/viral pneumonitis secondary to 
congenital rubella syndrome.  She was given 
Oxygen by nasal cannulae, cefotaxime and 
cloxacillin, the mother's expressed breast milk, 
and normal saline nasal drops.  Blood was 
collected for full blood count.  The mother was 
re-counseled and re-interviewed at which point 
she remembered that she had a rash at six weeks 
of pregnancy which she 'contracted' from a 
neighbour's child.  The full blood count results 
were as follows: HB – 11.9g/dl; Platelets – 
360,000; White blood count – 23,000; 
Lymphocytes – 12,280; and Neutrophils – 
6,610.
At 7 days post admission, her cough had 
subsided, probably a response to the treatment.  
She was breastfeeding well and her general 
condition was good.  Her physical examination 
revealed a head circumference of  34.5 cm – 
thway below the 5  centile; length 49 cm; weight 
th
for length <less than 5  centile; weight 2.6 kg; 
and heart rate 160/minutes.  She was discharged 
from hospital and the Ophthalmologist booked 
her for an operation to be done a month later.
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Following the confirmation of the above CRS 
case and sharing of information with clinicians 
at the pediatrics' departmental meeting, three 
more cases described below with symptoms 
and signs suggestive of CRS were identified 
and investigated.
Case 2
A three week old boy was admitted to the 
paediatrics ward with bilateral white papillary 
reflex, congenital heart disease and 
microcephaly.  ECHO showed patent ductus 
arteriosus. Ophthalmological examination 
confirmed bilateral cataracts. Serum rubella 
IgM was positive.
Case 3
A twelve week old girl was brought to the 
Paediatrics clinic for slow growth rate.  On 
physical examination, the baby though 
generally active and in good condition, had 
bilateral cataracts, microcephaly and 
developmental delay.  A serum sample was 
collected and tested in for rubella IgM.  The 
baby tested positive for rubella IgM. 
Case 4
A seven week old baby girl was seen at 
Paediatrics outpatients' clinic for failure to 
thrive, fever and difficulty in breathing.  She 
was treated for Pneumonia and Sepsis. Physical 
examination showed poor growth, and heart 
murmurs and bilateral cataracts.   Further 
evaluation showed; Patent ductus arteriosus on 
E C H O ,  a n d  b i l a t e r a l  c a t a r a c t s  o n  
ophthalmological evaluation.  The rubella IgM 
test was done at 8 weeks and revealed presence 
of rubella IgM antibodies.  At the time of the 
report, the patient had an appointment 
scheduled a month later. Discussion 
The four cases that we have documented give 
evidence of congenital rubella syndrome in 
Zambia.  CRS is a neonatal manifestation of 
intrauterine infection with rubella virus. The 
signs and symptoms, commonly PDA and 
cataracts in the cases described in this article 
along with laboratory confirmation of rubella 
IgM (indicating active infection) support this 
evidence.  Confirmed CRS is defined as a 
clinically consistent case whose symptoms 
include one or more specific signs and 
symptoms including cataracts or congenital 
glaucoma, congenital heart disease, hearing 
impairment, pigmentary retinopathy, purpura, 
hepatosplenomegaly, jaundice, microcephaly, 
developmental delay, meningoencephalitis, or 
radiolucent bone disease with a laboratory 
evidence [4, 7, 9-10].
Disease burden associated with Rubella 
infection has continued to be of great public 
health concern globally and is still a major and 
important cause of birth abnormalities.  
Maternal infection during pregnancy can lead to 
CRS in the foetus [4, 6].   Identification of 4 
cases within a space of nine months in a 
defined/limited geographic area confirmed 
circulation of rubella virus in Lusaka.  In 
comparison to the other infections such as 
Toxoplasmosis, Cytomegalovirus and Herpes 
in the TORCH infection group, suggests it is an 
important cause of congenital abnormalities [7, 
11-13].  Many children born with CRS will 
demonstrate persistent neuromotor deficits later 
in life.  Pneumonitis, Diabetes mellitus, thyroid 
dysfunctions, and progressive panencephalitis 
are other late expressions of CRS [14-17].  
Though the consequences of CRS are 
devastating and long lasting, supportive 
treatment can be given especially when detected 
early. [2, 17-18]. 
There is scanty information on the evidence of 
CRS in Zambia or even the prevalence of 
susceptible women to rubella infection in 
pregnancy.  Watts [6] documented an estimated 
12%prevalence of vulnerable mothers in 
Lusaka.  These estimates were used by Cutts 
and Vynnycky [5] to estimate a CRS incidence 
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rate of 123/100,000 live births. These statistics 
were reported more than a decade ago in one 
demographic area on a limited sample size.  
Data obtained through the measles surveillance 
program indicated that 21% of the rash and 
fever cases investigated were acutely infected 
with rubella virus in 2011 compared to 2.5% in 
2010 [19-20] suggesting an increase in the 
prevalence of CRS.  After literature search, it 
was established that the four cases that we have 
reported are the first laboratory-confirmed and 
documented cases of CRS in Zambia. Since 
CRS is a rare disease in immunized and non-
outbreak communities [17], the incidence rate 
in Zambia in which vaccination against rubella 
has not been conducted may be underestimated.  
The cases described in this paper strongly 
suggest evidence of rubella virus transmission 
amongst pregnant women in Zambia.  The 
symptoms observed in three of the four cases, 
particularly Patent Ductus Arteriosus are 
suggestive of intra-uterine infection at <20 
weeks gestation [6-7, 9].  The observations 
suggest presence of critical limitations in past 
and present surveillance efforts. 
CONCLUSION 
Congenital Rubella Syndrome (CRS) is a major 
public health problem among young women in 
childbearing age causing serious consequences 
including miscarriage, foetal death or an infant 
born with abnormalities.  The clinical 
symptoms and laboratory evidence of rubella 
infection confirmed congenital rubella 
syndrome in our four patients.  Although the 
disease is mild and probably missed, this 
requires urgent strategic public health 
responses especially that the effects and defects 
associated with infection are severe and mostly 
irreversible in children affected.  Though few 
cases are seen, the devastating consequences in 
the new-born are long lasting [9].  We suggest 
testing different interventions, one of which 
could be the use of a combined Measles-
Rubella vaccine (MR vaccine), a vaccine highly 
recommended by WHO and UNICEF and 
supported by GAVI [21-22] in national 
childhood immunization schedules.  A clear and 
well managed immunisation programme is 
important in ensuring success in control and 
eliminations of rubella as low vaccination 
coverage carries the theoretical risk of 
increasing the occurrence of congenital rubella. 
[23] There is an urgent need for surveillance of 
congenital rubella syndrome and a baseline 
rubella sero-prevalence survey in order to 
determine the burden of disease and use this 
data to direct policy in terms of interventions for 
treatment, control and possible elimination of 
rubella infection. 
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